(Q37469461)

20 August 2017

1 reference

title

Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. (English)

1 reference

20 August 2017

Daniel W Lin

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

27

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

315-321

1 reference

Prostate-specific antigen in clinical practice

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Quantifying the role of PSA screening in the US prostate cancer mortality decline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Percent free prostate-specific antigen for first-time prostate biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prostate-specific antigen velocity and repeated measures of prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Nucleic acid sequence-based amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

uPM3, a new molecular urine test for the detection of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

PCA3: a molecular urine assay for predicting prostate biopsy outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Early identification of individuals with prostate cancer in negative biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

EPCA-2: a highly specific serum marker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Gene silencing in cancer in association with promoter hypermethylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

The epigenomics of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Multigene methylation analysis for detection and staging of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Frequent hypermethylation of the RASSF1A gene in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Quantitative, spatial resolution of the epigenetic field effect in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Development of a multiplexed urine assay for prostate cancer diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

The role of SPINK1 in ETS rearrangement-negative prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.01.026

10.1016/J.UROLONC.2009.01.026

7 January 2021

Identifiers

DOI

1 reference

release_q3d4t3de5naj5nerrizhquv6xa

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q3d4t3de5naj5nerrizhquv6xa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference